+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Arthropod-borne Viral Infections Testing Market - Global Forecast 2025-2030- Product Image
Arthropod-borne Viral Infections Testing Market - Global Forecast 2025-2030- Product Image
Sale

Arthropod-borne Viral Infections Testing Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336731
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Arthropod-borne Viral Infections Testing Market is experiencing steady growth as public health, clinical, and research sectors focus on timely disease surveillance and resilient diagnostic infrastructure. Market forces are propelling innovation in test technologies and expanding access across diverse geographies.

Market Snapshot: Arthropod-borne Viral Infections Testing Market Overview

In 2024, the arthropod-borne viral infections testing market reached USD 12.18 billion, climbing to USD 13.52 billion in 2025, and is projected to achieve a compound annual growth rate (CAGR) of 10.91%, with an estimated value of USD 22.68 billion by 2030. The market’s momentum is being driven by rising outbreaks, broader geographic spread of vector-borne illnesses, and increased investment in diagnostic systems capable of rapid, precise detection. Stakeholder groups—including public health agencies, clinical laboratories, and research institutes—are investing in up-to-date testing platforms and scalable supply chains to maintain public health preparedness. Heightened vigilance, demand for innovation, and regulatory adjustments are influencing procurement and integration of the latest molecular and immunoassay solutions.

Scope & Segmentation of the Arthropod-borne Viral Infections Testing Market

This market research encompasses the multifaceted dimensions shaping how arthropod-borne viral infections are detected and managed across segments and global regions. Key segmentation includes:

  • Test Type: Antibody testing (IgG, IgM), Antigen testing (Elisa antigen, Rapid antigen), Molecular testing (Conventional PCR, Isothermal Amplification, Real Time PCR)
  • Technology: Immunoassay (Chemiluminescent Immunoassay, Elisa, Lateral Flow Immunoassay), Next Generation Sequencing (Illumina, Pyrosequencing), PCR-based technologies, Rapid Diagnostic Tests (Lateral Flow Assay, Optical Immunoassay)
  • End User: Academic Institutions, Diagnostic Centers, Hospital Laboratories, Reference Laboratories, Research Institutes
  • Sample Type: Blood serum, Cerebrospinal fluid, Plasma, Saliva, Whole blood
  • Disease Type: Chikungunya, Dengue, West Nile, Yellow Fever, Zika
  • Regions: Americas (United States—with leading states, Canada, Mexico, Brazil, Argentina), EMEA (United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, and additional markets)
  • Key Companies: F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., bioMérieux SA, DiaSorin S.p.A., Bio-Rad Laboratories, Inc., Abnova Corporation, AdvaCare Pharma, Chembio Diagnostics, Inc., EUROIMMUN AG by PerkinElmer Inc.

Key Takeaways for Senior Decision-Makers

  • Testing approaches have evolved, integrating molecular platforms and immunoassay techniques, which support both centralized laboratories and rapid point-of-care settings.
  • Segment differentiation highlights the strategic value of tailored diagnostics—certain technologies enable early detection while others provide retrospective surveillance.
  • Collaboration between leading diagnostics firms and biotechnology innovators is accelerating new assay development and strengthening production scalability.
  • Digital integration and laboratory automation are enhancing real-time analytics, boosting operational efficiency, and ensuring consistent compliance with quality standards.
  • Regional disparities in infrastructure and regulatory requirements are creating tailored adoption pathways, prompting manufacturers to balance global strategy with local adaptation.
  • Continuous workforce training and engagement with regulatory agencies are being prioritized to maintain proficiency and streamline approvals for novel diagnostics.

Tariff Impact

Recent United States tariff adjustments have influenced sourcing and procurement strategies within the arthropod-borne viral infections testing supply chain. Increased import duties on diagnostic reagents and instruments prompted a shift toward localized manufacturing and regionalized supply chains, minimizing exposure to trade fluctuations and supporting uninterrupted testing services. This market adaptation has encouraged deeper collaboration with local suppliers and broader diversification across supply bases, reducing vulnerability to future policy changes.

Research Methodology & Data Sources

A rigorous blend of primary and secondary research underpins this analysis. Extensive reviews of scientific literature, regulatory documents, and technical white papers were complemented by interviews with virology experts, diagnostics developers, and laboratory managers. Triangulation of input from multiple data sources, including supply chain specialists and procurement professionals, ensured robust validation and peer-reviewed reliability for market findings.

Why This Report Matters: Actionable Insights for Decision-Makers

  • Provides an in-depth, segmented market analysis empowering you to allocate resources efficiently and mitigate operational risk.
  • Enables strategic planning by outlining technology adoption patterns, regional nuances, and the impact of regulatory and trade shifts on diagnostics procurement.
  • Guides investment and innovation priorities by distilling key trends, tested market approaches, and successful partnership models for long-term resilience.

Conclusion

In today’s dynamic health landscape, this report offers the clarity and strategic perspective senior leaders require to shape future diagnostic initiatives and optimize their positions in the arthropod-borne viral infections testing market. Stay prepared and informed to advance organizational objectives and enhance diagnostic response.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of multiplex PCR panels enabling simultaneous detection of dengue chikungunya and Zika viruses
5.2. Adoption of portable point-of-care diagnostic devices with CRISPR-based arboviral detection technology
5.3. Expansion of at-home test kits for mosquito-borne virus screening with smartphone connectivity
5.4. Implementation of AI-driven predictive analytics platforms for real-time outbreak surveillance and testing prioritization
5.5. Development of next-generation serological assays differentiating cross-reactive flavivirus antibodies in endemic regions
5.6. Partnerships between diagnostic companies and global health organizations for scalable arboviral testing in resource-limited settings
5.7. Regulatory approvals accelerating commercialization of high-throughput automated platforms for large-scale arbovirus screening
5.8. Research advances in nanopore sequencing for direct RNA identification of emerging mosquito-borne viruses in field settings
5.9. Increased government funding for establishing sentinel testing networks and genomic surveillance of arthropod-borne viruses
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Arthropod-borne Viral Infections Testing Market, by Test Type
8.1. Introduction
8.2. Antibody Testing
8.2.1. IgG Antibody
8.2.2. IgM Antibody
8.3. Antigen Testing
8.3.1. Elisa Antigen
8.3.2. Rapid Antigen
8.4. Molecular Testing
8.4.1. Conventional PCR
8.4.2. Isothermal Amplification
8.4.3. Real Time PCR
9. Arthropod-borne Viral Infections Testing Market, by Technology
9.1. Introduction
9.2. Immunoassay
9.2.1. Chemiluminescent Immunoassay
9.2.2. Elisa
9.2.3. Lateral Flow Immunoassay
9.3. Next Generation Sequencing
9.3.1. Illumina Sequencing
9.3.2. Pyrosequencing
9.4. PCR Based Technologies
9.4.1. Conventional PCR
9.4.2. Isothermal Amplification
9.4.3. Real Time PCR
9.5. Rapid Diagnostic Test
9.5.1. Lateral Flow Assay
9.5.2. Optical Immunoassay
10. Arthropod-borne Viral Infections Testing Market, by End User
10.1. Introduction
10.2. Academic Institutions
10.3. Diagnostic Centers
10.4. Hospital Laboratories
10.5. Reference Laboratories
10.6. Research Institutes
11. Arthropod-borne Viral Infections Testing Market, by Sample Type
11.1. Introduction
11.2. Blood Serum
11.3. Cerebrospinal Fluid
11.4. Plasma
11.5. Saliva
11.6. Whole Blood
12. Arthropod-borne Viral Infections Testing Market, by Disease Type
12.1. Introduction
12.2. Chikungunya
12.3. Dengue
12.4. West Nile
12.5. Yellow Fever
12.6. Zika
13. Americas Arthropod-borne Viral Infections Testing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Arthropod-borne Viral Infections Testing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Arthropod-borne Viral Infections Testing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.2. Abbott Laboratories
16.3.3. Thermo Fisher Scientific Inc.
16.3.4. bioMérieux SA
16.3.5. DiaSorin S.p.A.
16.3.6. Bio-Rad Laboratories, Inc.
16.3.7. Abnova Corporation
16.3.8. AdvaCare Pharma
16.3.9. Chembio Diagnostics, Inc.
16.3.10. EUROIMMUN AG by PerkinElmer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET: RESEARCHAI
FIGURE 26. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET: RESEARCHSTATISTICS
FIGURE 27. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET: RESEARCHCONTACTS
FIGURE 28. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 163. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 164. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 165. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 166. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 167. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 168. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 169. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 170. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 171. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 172. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 173. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 174. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 175. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 176. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 177. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 178. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 179. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 180. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 181. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 184. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 185. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 186. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Arthropod-borne Viral Infections Testing market report include:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • DiaSorin S.p.A.
  • Bio-Rad Laboratories, Inc.
  • Abnova Corporation
  • AdvaCare Pharma
  • Chembio Diagnostics, Inc.
  • EUROIMMUN AG by PerkinElmer Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 13.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.68 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Arthropod-Borne Viral Infection Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Arthropod-Borne Viral Infection Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Peters' Atlas of Tropical Medicine and Parasitology. Edition No. 7 - Product Image

Peters' Atlas of Tropical Medicine and Parasitology. Edition No. 7

  • Book
Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10 - Product Image

Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10

  • Book
Modernizing Global Health Security to Prevent, Detect, and Respond - Product Image

Modernizing Global Health Security to Prevent, Detect, and Respond

  • Book
  • Global
Ectoparasitic Diseases - Product Image

Ectoparasitic Diseases

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.